Publication date: 24/09/2018
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that the Company will present on 26 September at the 26th Annual Meeting of the European Orthopaedic Research Society (EORS), in Galway, Ireland.
The Annual EORS Meeting is Europe's Summit for orthopaedic research and is attended by scientists, clinicians and entrepreneurs in the field. In the oral presentation, Bone Therapeutics will highlight recent preclinical in vitro and in vivo results demonstrating the potent osteogenic properties of its allogeneic bone-forming cell therapy platform to promote bone-formation and improve fracture healing in relevant models.
Oral Presentation Details:
Title Presentation: Injectable human bone-forming cells derived from bone marrow MSC display potent osteogenic properties
Session: Mesenchymal Stem Cells
Session Date & Time: Wednesday, 26 September 2018, at 4pm CEST (3pm BST)
Location: Veranda room of the Galmont Hotel & Spa, Lough Atalia Road H91 CYN3, Galway, Ireland
Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
The Company’s primary clinical focus is ALLOB, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.